Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study

(2012) S. E. Nielsen et al.   DIABETIC MEDICINE

Aldosterone: Role in Edematous Disorders, Hypertension, Chronic Renal Failure, and Metabolic Syndrome

(2010) R. W. Schrier et al.   Clinical Journal of the American Society of Nephrology

Aldosterone 'escape' vs 'breakthrough'

(2010) Robert W. Schrier   Nature Reviews Nephrology

Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial

(2008) Leszek Tylicki et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years: Association with mortality and decline of glomerular filtration rate

(2008) A. S. Astrup et al.   DIABETES CARE

Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients

(2008) Carmine Savoia et al.   HYPERTENSION

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

(2008) Frederik Persson et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis

(2008) A. Syngle et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY